23-10-2024 | Air Embolism | RESEARCH LETTER
Early insights on adverse events associated with PulseSelect™ and FARAPULSE™: analysis of the MAUDE database
Authors:
Pragyat Futela, Gurukripa N. Kowlgi, Christopher V. DeSimone, Ammar M. Killu, Konstantinos C. Siontis, Peter A. Noseworthy, Suraj Kapa, Abhishek J. Deshmukh
Published in:
Journal of Interventional Cardiac Electrophysiology
Login to get access
Excerpt
Pulsed-field ablation (PFA) offers a novel approach to myocardial tissue ablation with enhanced cardiac tissue selectivity [
1]. PulseSelect™ (Medtronic Inc., Minneapolis, MN) and FARAPULSE™ (Farapulse-Boston Scientific Inc., Menlo Park, CA) are PFA systems that received Food and Drug Administration (FDA) approval on December 13, 2023, and January 31, 2024, respectively, for the treatment of paroxysmal atrial fibrillation [
1,
2]. …